View in EDS

P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial.

Saved in:
Bibliographic Details
Title: P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial.
Authors: Wolinsky, J.S.1 (AUTHOR), Hartung, H.P.1 (AUTHOR), Brochet, B.1 (AUTHOR), Montalban, X.1 (AUTHOR), Naismith, R.T.1 (AUTHOR), Manfrini, M.1 (AUTHOR), Garas, M.1 (AUTHOR), Model, F.1 (AUTHOR), Hubeaux, S.1 (AUTHOR), Kappos, L.1 (AUTHOR), Hauser, S.L.1 (AUTHOR)
Source: Clinical Neurophysiology. Aug2019, Vol. 130 Issue 8, pe170-e171. 2p.
Database: Academic Search Ultimate
Description
ISSN:13882457
DOI:10.1016/j.clinph.2019.04.704